Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity

References

• Ofek K, Soreq H. Cholinergic involvement and manipulation approaches in multiple system disorders. Chem Biol Interact 2013;203:113–19.
   PubMed Web of Science ®Google Scholar
• Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 2006;7:73.
   PubMed Web of Science ®Google Scholar
• Pieper MP. The non-neuronal cholinergic system as novel drug target in the airways. Life Sci 2012;91:1113–18.
   PubMed Web of Science ®Google Scholar
• Giacobini E. Butyrylcholinesterase: its role in brain function. In: Giacobini E. ed. Butyrylcholinesterase; its function and inhibitors. 1st ed. London: Martin Dunitz; 2003:1–20.
   Google Scholar
• Katalinić M, Hrvat NM, Karasova JZ, et al. Translation of in vitro to in vivo pyridinium oxime potential in tabun poisoning. Arh Hig Rada Toksikol 2015;66:291–8.
   PubMed Web of Science ®Google Scholar
• Lockridge O, Norgren RB Jr, Johnson RC, Blake TA. Naturally occurring genetic variants of human acetylcholinesterase and butyrylcholinesterase and their potential impact on the risk of toxicity from cholinesterase inhibitors. Chem Res Toxicol 2016;29:1381–92.
   PubMed Web of Science ®Google Scholar
• Gazić I, Bosak A, Šinko G, et al. Preparative HPLC separation of bambuterol enantiomers and stereoselective inhibition of human cholinesterases. Anal Bioanal Chem 2006;385:1513–19.
   PubMed Web of Science ®Google Scholar
• Soreq H, Seidman S. Acetylcholinesterase-new roles for an old actor. Nat Rev Neurosci 2001;2:294–302.
   PubMed Web of Science ®Google Scholar
• Bosak A, Gazić-Smilović I, Šinko G, et al. Metaproterenol, isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors. J Med Chem 2012;55:6716–23.
   PubMed Web of Science ®Google Scholar
• Reiner E, Bosak A, Simeon-Rudolf V. Activity of cholinesterases in human whole blood measured with acetylthiocholine as substrate and ethopropazine as selective inhibitor of plasma butyrylcholinesterase. Arh Hig Rada Toksikol 2004;55:1–4.
   PubMedGoogle Scholar
• Tunek A, Svensson LA. Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterases in human blood. Drug Metab Dispos 1988;16:759–64.
   PubMed Web of Science ®Google Scholar
• Ballard CL, Perry EK. The role of butyrylcholinesterase in Alzheimer’s disease. In: Giacobini E, ed. Butyrylcholinesterase; its function and inhibitors. London: Martin Dunitz; 2003:123–148.
   Google Scholar
• Katalinić M, Bosak A, Kovarik Z. Flavonoids as inhibitors of human butyrylcholinesterase variants. Food Technol Biotech 2014;52:64–7.
   Web of Science ®Google Scholar
• McGehee DS, Krasowski MD, Fung DL, et al. Cholinesterase inhibition by potato glycoalkaloids slows mivacurium metabolism. Anesthesiology 2000;93:510–19.
   PubMed Web of Science ®Google Scholar
• Kovarik Z, Radić Z, Grgas B, et al. Amino acid residues involved in the interaction of acetylcholinesterase and butyrylcholinesterase with the carbamates Ro 02-0683 and bambuterol, and with terbutaline. Biochem Biophys Acta 1999;1433:261–71.
   PubMed Web of Science ®Google Scholar
• Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Therapeut 2015;148:34–46.
   PubMed Web of Science ®Google Scholar
• Simeon-Rudolf V, Šinko G, Štuglin A, Reiner E. Inhibition of human blood acetylcholinesterase and butyrylcholinesterase by ethopropazine. Croat Chem Acta 2001;74:173–82.
   Web of Science ®Google Scholar
• Cruz PMR, Palace J, Ramjattan H, et al. Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes. Neurology 2015;85:1043–7.
   PubMed Web of Science ®Google Scholar
• Barrot M, Yalcin I, Choucair-Jaafar N, et al. From antidepressant drugs to beta-mimetics: preclinical insights on potential new treatments for neuropathic pain. Recent Pat CNS Drug Discov 2009;4:182–9.
   PubMedGoogle Scholar
• Gundavarapu S, Zhuang J, Barrett EG, et al. A critical role of acute bronchoconstriction in the mortality associated with high-dose inhalation: effects of epinephrine and oxygen therapies. Toxicol Appl Pharm 2014;274:200–8.
   PubMed Web of Science ®Google Scholar
• Bhattacharya R, Kumar P, Jeevaratnam K, et al. Therapeutic evaluation of bronchodilators as an adjunct against organophosphorus intoxication in mice. Asia Pac J Pharmacol 1991;6:75–80.
   Google Scholar
• Jin S, Kumar SS, Youngnam NJ, et al. An in vivo zebrafish screen identifies organophosphate antidotes with diverse mechanism of action. J Biomol Screen 2013;18:108–15.
   PubMed Web of Science ®Google Scholar
• Perkins MW, Wong B, Rodriguez A, et al. Inhalation toxicity of soman vapor in non-anesthetized rats: a preliminary assessment of inhaled bronchodilator or steroid therapy. Chem Biol Interact 2013;206:452–61.
   PubMed Web of Science ®Google Scholar
• Boudinot E, Taysse L, Daulon S, et al. Effects of acetylcholinesterase and butyrylcholinesterase inhibition on breathing in mice adopted or not to reduced acetylcholinesterase. Pharmacol Biochem 2005;80:53–61.
   PubMed Web of Science ®Google Scholar
• Patel M, Thomson NC. Levosalbutamol for chronic obstructive pulmonary disease: a treatment evaluation. Expert Opin Pharmacother 2012;13:1069–75.
   PubMed Web of Science ®Google Scholar
• Källström BL, Sjöberg J, Waldeck B. Steric aspects of formoterol and terbutaline: is there an adverse effect of the distomer on airway smooth muscle function? Chirality 1996;8:567–73.
   PubMed Web of Science ®Google Scholar
• Bosak A, Gazić I, Vinković V, Kovarik Z. Stereoselective inhibition of human, mouse, and horse cholinesterases by bambuterol enantiomers. Chem Biol Interact 2008;175:192–5.
   PubMed Web of Science ®Google Scholar
• Bosak A, Smilović IG, Štimac A, et al. Peripheral anionic site and acyl pocket define selective inhibition of butyrylcholinesterase by two biscarbamates. Arch Biochem Biophys 2013;529:140–5.
   PubMed Web of Science ®Google Scholar
• Kovarik Z, Simeon-Rudolf V. Interaction of human butyrylcholinesterase variants with bambuterol and terbutaline. J Enzym Inhib Med Chem 2004;19:113–17.
   PubMed Web of Science ®Google Scholar
• Evans RT, McQueen MJ. Cholinesterase phenotyping: clinical aspects and laboratory applications. Crit Rev Clin Lab Sci 1986;23:35–64.
   PubMed Web of Science ®Google Scholar
• Kovarik Z, Simeon-Rudolf V. An improvement in segregation of human butyrylcholinesterase phenotypes having the fluoride-resistant variants. Arh Hig Rada Toksikol 2003;54:239–44.
   PubMedGoogle Scholar
• Gao Y, Zepp CM. Enantioselective preparation of optically pure albuterol via resolution of methyl 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-hydroxybenzoate with ditoluoyltartaric acid. US Patent No. 1995/005399765A. 1995.
   Google Scholar
• Rong Y, Ruoho AE. A new synthetic approach to salmeterol. Synth Commun 1999;29:2155–62.
   Web of Science ®Google Scholar
• Liao J, Peng X, Zhang J, et al. Facile resolution of racemic terbutaline and a study of molecular recognition through chiral supramolecules based on enantiodifferentiating self-assembly. Org Biomol Chem 2003;1:1080–5.
   PubMed Web of Science ®Google Scholar
• Kontrec D, Vinković V, Šunjić V, et al. Enantioseparation of racemic 4-aryl-3,4-dihydro-2(1H)-pyrimidones on chiral stationary phases based on 3,5-dimethylanilides of N-(4-alkylamino-3,5-dinitro)benzoyl L-alpha-amino acids. Chirality 2003;15:550–7.
   PubMed Web of Science ®Google Scholar
• Coe DM, Perciaccante R, Procopiou PA. Potassium trimethylsilanolate induced cleavage of 1,3-oxazolidin-2- and 5-ones, and application to the synthesis of (R)-salmeterol. Org Biomol Chem 2003;1:1106–11.
   PubMed Web of Science ®Google Scholar
• Beigi F, Bertucci C, Zhu W, et al. Enantioselective separation and online affinity chromatographic characterization of R,R- and S,S-fenoterol. Chirality 2001;8:822–7.
   Google Scholar
• Ellman GL, Courtney KD, Andres V, Featherstone RMA. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Kovarik Z, Ciban N, Radić Z, et al. Active site mutant acetylcholinesterase interactions with 2-PAM, HI-6, and DDVP. Biochem Biophys Res Commun 2006;342:973–8.
   PubMed Web of Science ®Google Scholar
• Kryger G, Harel M, Giles K, et al. Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr D Biol Crystallogr 2000;56:1385–94.
   PubMedGoogle Scholar
• Ngamelue MN, Homma K, Lockridge O, et al. Crystallization and X-ray structure of full-length recombinant human butyrylcholinesterase. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun 2007;63:723–7.
   PubMedGoogle Scholar
• Maraković N, Knežević A, Vinković V, et al. Design and synthesis of N-substituted-2-hydroxyiminoacetamides and interactions with cholinesterases. Chem Biol Interact 2016;259:122–32.
   PubMed Web of Science ®Google Scholar
• Katalinić M, Rusak G, Domaćinović Barović J, et al. Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. Eur J Med Chem 2010;45:186–92.
   PubMed Web of Science ®Google Scholar
• Saxena A, Fedorko JM, Vinayaka CR, et al. Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept®) to cholinesterases. Febs J 2003;270:4447–58.
   Web of Science ®Google Scholar
• Bosak A, Primožič I, Oršulić M, et al. Enantiomers of quinuclidin-3-ol derivatives: resolution and interactions with human cholinesterases. Croat Chem Acta 2005;78:121–8.
   Web of Science ®Google Scholar
• Giacobini E, Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer’s disease and related disorders. In: Giacobini E. and Pepeu G. eds. The brain cholinergic system in health and disease. Abingdon: Informa Healtcare; 2006;235–264.
   Google Scholar